Shattuck Labs (Nasdaq:STTK) - Cotización, noticias y análisis

Resumen de acción STTK

Shattuck Labs, Inc. es una empresa biotecnológica en fase clínica que desarrolla terapias para el tratamiento del cáncer y las enfermedades autoinmunes en Estados Unidos.

Acerca de la empresa

STTK fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 63.11%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 22.2% al año durante los próximos 3 años

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene ingresos significativos ($2M)

Competidores de Shattuck Labs, Inc.

Humacyte

NasdaqGS:HUMA

US$540.6m

Editas Medicine

NasdaqGS:EDIT

US$465.4m

Mereo BioPharma Group

NasdaqCM:MREO

US$434.1m

Lexeo Therapeutics

NasdaqGM:LXEO

US$435.2m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Shattuck Labs
Historical stock prices
Current Share Price	US$11.18
52 Week High	US$11.62
52 Week Low	US$1.33
Beta	2.13
1 Month Change	20.09%
3 Month Change	14.90%
1 Year Change	314.07%
3 Year Change	-59.05%
5 Year Change	n/a
Change since IPO	-42.22%

Noticias y actualizaciones recientes

Recent updates

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 18

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Feb 25

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Nov 23

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Aug 24

Shattuck Labs names Abhinav Shukla as chief technical officer

Jun 01

Shattuck Labs EPS beats by $0.11, beats on revenue

May 10

Here's Why We're Not Too Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

May 07

Could The Shattuck Labs, Inc. (NASDAQ:STTK) Ownership Structure Tell Us Something Useful?

Mar 08

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely

Jan 12

Shattuck Labs reports Q3 results

Nov 13

Rentabilidad de los accionistas

	STTK	US Biotechs	Mercado US
7D	1.9%	4.4%	0.6%
1Y	314.1%	2.8%	23.9%

Rentabilidad vs. Industria: STTK superó al sector US Biotechs , que obtuvo un rendimiento del -2.3% el año pasado.

Rentabilidad vs. Mercado: STTK superó al mercado US, que obtuvo un rendimiento del 24.9% el año pasado.

Volatilidad de los precios

Is STTK's price volatile compared to industry and market?
STTK volatility
STTK Average Weekly Movement	10.0%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de STTK ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de STTK ha disminuido de 23% a 10% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	75	Taylor Schreiber	www.shattucklabs.com

Shattuck Labs, Inc. es una empresa biotecnológica en fase clínica que desarrolla terapias para el tratamiento del cáncer y las enfermedades autoinmunes en Estados Unidos. El principal candidato a producto de la empresa es SL-172154, que se encuentra en fase 1 de ensayo clínico para el tratamiento de los cánceres de ovario, trompa de Falopio y peritoneal. Shattuck Labs, Inc. se constituyó en 2016 y tiene su sede en Austin (Texas).

Resumen de fundamentos de Shattuck Labs, Inc.

¿Cómo se comparan los beneficios e ingresos de Shattuck Labs con su capitalización de mercado?
Estadísticas fundamentales de STTK
Capitalización bursátil	US$531.62m
Beneficios(TTM)	-US$85.08m
Ingresos (TTM)	US$2.72m

195.8x

Ratio precio-ventas (PS)

-6.2x

Ratio precio-beneficio (PE)

¿Está STTK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de STTK
Ingresos	US$2.72m
Coste de los ingresos	US$74.01m
Beneficio bruto	-US$71.29m
Otros gastos	US$13.78m
Beneficios	-US$85.08m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.79
Margen bruto	-2,625.97%
Margen de beneficio neto	-3,133.63%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado STTK a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción STTK

Recompensas

Análisis de riesgos

Competidores de Shattuck Labs, Inc.

NasdaqGS:HUMA

US$540.6m

NasdaqGS:EDIT

US$465.4m

NasdaqCM:MREO

US$434.1m

NasdaqGM:LXEO

US$435.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Recent updates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2024

Consensus revenue estimates increase by 170%

General Counsel notifies of intention to sell stock

Insufficient new directors

Shattuck Labs, Inc. Announces Board Appointments

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Financial Officer recently sold US$250k worth of stock

Chief Financial Officer notifies of intention to sell stock

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

New minor risk - Shareholder dilution

Shattuck Labs, Inc. has filed a Follow-on Equity Offering in the amount of $30.000001 million.

Price target increased by 21% to US$15.50

New major risk - Financial position

Consensus revenue estimates increase by 78%, EPS downgraded

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shattuck Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Shattuck Labs, Inc. to Present Topline Data from Phase 1 A/B Clinical Trial of Sl-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (Aml) and Higher-Mds) Patients At the American Society of Hematology (Ash) 2023 Annual Meeting

Consensus revenue estimates increase by 16%

Price target decreased by 21% to US$12.80

Consensus revenue estimates decrease by 11%

Consensus revenue estimates increase by 91%

New minor risk - Market cap size

Can Shattuck Labs (NASDAQ:STTK) Afford To Invest In Growth?

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$2.03 loss

We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Shattuck Labs, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Consensus forecasts updated

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 264%

High number of new directors

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.41 loss in 3Q 2021)

Shattuck Labs, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.56 loss in 2Q 2021)

Shattuck Labs GAAP EPS of -$0.65 misses by $0.06

We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate

Shattuck Labs, Inc.(NasdaqGS:STTK) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$25.50

High number of new directors

Shattuck Labs, Inc., Annual General Meeting, Jun 07, 2022

Shattuck Labs Presents Preclinical Data At the 2022 American Association for Cancer Research (AACR) Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Shattuck Labs, Inc. (NASDAQ:STTK) Just Reported And Analysts Have Been Cutting Their Estimates

Price target decreased to US$39.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?

Rosen Law Firm Files Securities Class Action Lawsuit Against Shattuck Labs, Inc

Lead Independent Director recently bought US$56k worth of stock

Will Shattuck Labs (NASDAQ:STTK) Spend Its Cash Wisely?

Chief Financial Officer exercised options to buy US$250k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$1.54 loss in 3Q 2020)

High number of new and inexperienced directors

General Counsel notifies of intention to sell stock

We Think Shattuck Labs (NASDAQ:STTK) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$2.31m